IP Library Granted Patent US 9,205,136
Granted Patent B2
US 9,205,136 · App. 14/152,544 · Granted Dec 8, 2015

Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis

Inventors: Paul Schimmel (La Jolla, CA); Keisuke Wakasugi (Shizuoka, JP)
Assignee: The Scripps Research Institute
A61K38/53C07H21/04C12N9/93A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,205,136
App. No.
14/152,544
Granted
Dec 8, 2015
Kind
B2
Abstract

Methods of enhancing angiogenesis utilizing carboxy-terminal truncated human tyrosyl-tRNA synthetase (TyrRS) are disclosed. The truncated human TyrRS polypeptides comprise residues 1-364 or residues 1-343 of full length human TyrRS (SEQ ID NO: 2).

Claims (12)

1. A method for enhancing angiogenesis in a mammal to achieve a therapeutic effect; the method comprising the step of administering to the mammal an effective amount of a polypeptide which consists essentially of residues 1 to 364 of SEQ ID NO:2 or a dimer thereof encoded by a nucleic acid comprising a coding region consisting of a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a polynucleotide encoding a polypeptide consisting of amino acid residues 1-364 of SEQ ID NO: 2;

(b) a polynucleotide consisting of nucleotide residues 3428-4519 of SEQ ID NO: 1, which encodes amino acid residues 1-364 of SEQ ID NO: 2; and

(c) a polynucleotide that is hybridizable to a polynucleotide consisting of nucleotide residues 3428-4519 of SEQ ID NO: 1, which encodes amino acid residues 1-364 of SEQ ID NO: 2.

2. The method of claim 1 wherein the polypeptide consists essentially of residues 1 to 364 of SEQ ID NO:2 or a dimer thereof.

3. The method of claim 1 wherein the therapeutic effect comprises enhancing angiogenesis in a tissue graft in the mammal.

4. A method of treating a condition that would benefit from increased angiogenesis in a mammal comprising the step of administering to the mammal an angiogenically effective amount of a polypeptide which consists essentially of residues 1 to 364 of SEQ ID NO:2 or a dimer thereof encoded by a nucleic acid comprising a coding region consisting of a nucleotide sequence at least 95 % identical to a sequence selected from the group consisting of:

(a) a polynucleotide encoding a polypeptide consisting of amino acid residues 1-364 of SEQ ID NO: 2;

(b) a polynucleotide consisting of nucleotide residues 3428-4519 of SEQ ID NO: 1, which encodes amino acid residues 1-364 of SEQ ID NO: 2; and

(c) a polynucleotide that is hybridizable to a polynucleotide consisting of nucleotide residues 3428-4519 of SEQ ID NO: 1, which encodes amino acid residues 1-364 of SEQ ID NO: 2.

5. The method of claim 4 wherein the polypeptide consists essentially of residues 1 to 364 of SEQ ID NO:2 or a dimer thereof.

6. The method of claim 4 wherein the condition that would benefit from increased angiogenesis comprises a myocardial infarction.

Assignments (1)
CONFIRMATORY LICENSE Recorded Mar 31, 2014
From: THE SCRIPPS RESEARCH INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 032568/0526 →
Continuity (4)
Division 11590434 · Oct 31, 2006
Division 10240527
Provisional Application 60193471 · Mar 31, 2000
Related Publication 20140127183A1 · May 8, 2014